首页> 外文OA文献 >Comparison of the pharmacokinetics, safety and tolerability of two concentrations of a new liquid recombinant human growth hormone formulation versus the freeze-dried formulation

【2h】

Comparison of the pharmacokinetics, safety and tolerability of two concentrations of a new liquid recombinant human growth hormone formulation versus the freeze-dried formulation

机译：比较两种浓度的新型液体重组人生长激素制剂与冻干制剂的药代动力学，安全性和耐受性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Bernd Liedert; Ulf Forssmann; Peter Wolna; Michaela Golob; Andreas Kovar;
展开▼
作者单位

展开▼
年度 2010
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Comparison of the pharmacokinetics, safety and tolerability of two concentrations of a new liquid recombinant human growth hormone formulation versus the freeze-dried formulation [J] . Bernd Liedert, Ulf Forssmann, Peter Wolna, BMC Pharmacology and Toxicology . 2010,第1期

机译：比较两种浓度的新型液体重组人生长激素制剂与冻干制剂的药代动力学，安全性和耐受性
2. Open-Label, Randomized, Two-Way, Crossover Study Assessing the Bioequivalence of the Liquid Formulation versus the Freeze-Dried Formulation of Recombinant Human FSH and Recombinant Human LH in a Fixed 2:1 Combination (Pergoveris ?) in Pituitary-Suppressed Healthy Women [J] . Wilhelmina Bagchus, ?zkan Yalkinoglu, Peter Wolna Frontiers in Endocrinology . 2017,第1期

机译：开放标签，随机，双向交叉研究评估固定比例2：1组合中重组人FSH和重组人LH的液体制剂与冷冻干燥制剂的生物等效性（Pergoveris ？垂体抑制的健康女性
3. A novel sustained-release formulation of recombinant human growth hormone and its pharmacokinetic, pharmacodynamic and safety profiles [J] . WeiY., WangY., KangA., Molecular pharmaceutics . 2012,第7期

机译：重组人生长激素的新型缓释制剂及其药代动力学，药效动力学和安全性概况
4. Safety, tolerability, pharmacodynamics and pharmacokinetics following single subcutaneous dosesof a teverelix depot formulation in healthy male volunteers [C] . C. MacLean, F. Larsen, R. Piechatzek, Annual meeting exposition of the Controlled Release Society . 2005

机译：在健康男性志愿者中单次皮下注射Teverelix储库制剂后的安全性，耐受性，药效动力学和药代动力学
5. In vivo study with a novel liposomal formulation of a recombinant ADAM disintegrin-like domain showing both anti-angiogenic and tumor growth inhibition activities. [D] . Zidovetzki, Sam. 2009

机译：重组ADAM整合素样结构域的新型脂质体制剂的体内研究显示了抗血管生成和肿瘤生长抑制活性。
6. Comparison of the pharmacokinetics safety and tolerability of two concentrations of a new liquid recombinant human growth hormone formulation versus the freeze-dried formulation [O] . Bernd Liedert, Ulf Forssmann, Peter Wolna, 2010

机译：比较两种浓度的新型液体重组人生长激素制剂与冻干制剂的药代动力学安全性和耐受性
7. Comparison of the pharmacokinetics, safety and tolerability of two concentrations of a new liquid recombinant human growth hormone formulation versus the freeze-dried formulation [O] . Liedert, Bernd, Forssmann, Ulf, Wolna, Peter, 2010

机译：比较两种浓度的新型液体重组人生长激素制剂与冻干制剂的药代动力学，安全性和耐受性
8. Safety, Tolerability, and Antibody Responses in Humans After Sequential Immunization with a PfCSP DNA Vaccine Followed by the Recombinant Protein Vaccine RTS,S/AS02A [R] . Epstein, J. E. , Charoenvit, Y. , Kester, K. E. , 2004

机译：使用重组蛋白疫苗RTs，s / as02a后用pfCsp DNa疫苗连续免疫后人类的安全性，耐受性和抗体反应

Comparison of the pharmacokinetics, safety and tolerability of two concentrations of a new liquid recombinant human growth hormone formulation versus the freeze-dried formulation

著录项

引文网络

相似文献

相关主题

期刊订阅